Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review.

Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review. Hellenic J Cardiol. 2018 Feb 02;: Authors: Karvelas G, Roumpi A, Komporozos C, Syrigos K Abstract Everolimus (EVE) is now approved by many agencies for the treatment of variable neoplasms. The risk of adverse events with these agent is not adequately defined. The purpose of this review was to summarize the everolimus - induced cardiotoxic effects to patients that received the specific drug as an antineoplastic factor and evaluate any possible anti-atherogenic effects due to systemic use of the drug. PubMed was searched for articles until August 2017. Articles included an expanded-access clinical trial, as well as phase 2 or 3 clinical trials (most of them were randomized). There were also included 3 experimental studies, providing evidence for everolimus possible anti-atherogenic action. Only articles evaluating the systemic use of the drug were included. In order to be eligible, the trials should evaluate patients with malignancy, treated by everolimus or assess the anti-atherogenic impact of everolimus' systemic use in clinical or experimental studies. Only articles written in English language were included. No direct cardiotoxic adverse effects (arrhythmia, acute coronary event, heart failure, echocardiography pathologic findings) were reported. Patients appeared to be in danger of evolving adverse events that could relate to risk...
Source: Hellenic Journal of Cardiology - Category: Cardiology Tags: Hellenic J Cardiol Source Type: research